Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.

Jiayi ZhouXiaojuan PeiYingui YangZhu WangWeijie GaoRan YeXiantong ZhangJiangang LiuZhuohao LiuXinzhi YangJingli TaoChunshan GuWei HuFranky Lueng ChanXin LiJie MaoDinglan Wu

Published in: Journal for immunotherapy of cancer (2021)

TLX contributes to glioma malignancy and immunosuppression through transcriptional activation of PD-L1 ligands that bind to PD-1 expressed on both TILs and TAMs. Thus, targeting the druggable TLX may have potential therapeutic significance in glioma immune therapy.

Keyphrases

gene expression
transcription factor
stem cells
cancer therapy
drug delivery
mesenchymal stem cells
oxidative stress
binding protein